Nanobiotix (0QAV) Price & Analysis

4 Followers

0QAV Stock Chart & Stats

€28.82

-€0.07(-2.36%)

At close: Jan 09 4:00 PM EST

€28.82

-€0.07(-2.36%)

Day’s Range― - ―

52-Week Range€7.00 - €47.60

Previous CloseN/A

Volume19.00

Average Volume (3M)47.85K

Market Cap

€1.93B

Enterprise Value€986.13

Total Cash (Recent Filing)€52.75M

Total Debt (Recent Filing)€95.32M

Price to Earnings (P/E)―

Beta0.65

Next Earnings

Sep 30, 2026

EPS Estimate

-0.25

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.51

Shares Outstanding50,619,583

10 Day Avg. Volume62,181

30 Day Avg. Volume47,854

Financial Highlights & Ratios

PEG Ratio0.59

Price to Book (P/B)-10.94

Price to Sales (P/S)31.19

P/FCF Ratio-27.22

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€55.00

Price Target Upside90.84% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-0.35

Revenue Forecast (FY)€34.90M

Bulls Say, Bears Say

Bulls Say

Proprietary Oncology Nanoparticle PlatformNBTXR3 offers a differentiated approach to cancer treatment by combining nanoparticle technology with radiotherapy. If clinical validation continues, the platform could support multiple indications and create durable partnering or licensing opportunities.

Strategic Partnership With JanssenThe Janssen relationship provides access to a large pharmaceutical partner for development and potential commercialization. Such collaboration can improve execution, reduce some funding demands, and create milestone or royalty potential if the program advances.

Potential For Top-line ExpansionThe sharp 2025 revenue increase indicates that collaboration, licensing, or development-related receipts can materially expand the top line. While the pattern is not yet consistent, it demonstrates commercial potential beyond a purely pre-revenue profile.

Bears Say

Negative Equity And Rising DebtPersistent negative equity and higher debt weaken financial flexibility and increase dependence on external capital. This structure may constrain investment capacity and leave the company more exposed to dilution, refinancing needs, or funding disruptions.

Persistent Cash BurnOngoing operating and free-cash-flow losses show that the business cannot currently fund development from internal operations. Continued clinical investment will therefore require financing, partnerships, or other capital sources, creating execution and funding risk.

Unprofitable And Volatile Financial PerformanceThe company lacks stable, repeatable earnings power despite 2025 revenue growth. Persistent operating and net losses make results dependent on irregular collaboration or licensing receipts, reducing visibility into sustainable profitability over the medium term.

Nanobiotix News

Nanobiotix Updates Market on Share Capital and Voting Rights Structure

Nanobiotix ( ($FR:NANO) ) just unveiled an announcement. Nanobiotix reported that as of June 30, 2026, it had...

22d ago

Nanobiotix Reaffirmed at Buy on Strengthened Balance Sheet and Strategic Shift Toward Nanoprimer Platform Growth

Stifel Nicolaus analyst Clémence Thiers reiterated a Buy rating on Nanobiotix today and set a price target of...

3M ago

NBTX

Nanobiotix falls -9.0%

Nanobiotix (NBTX) is down -9.0%, or -$3.88 to $39.28. Published first on TheFly – the ultimate source for...

3M ago

NBTX

Nanobiotix announces EUR 75M global follow-on offering

Nanobiotix (NBTX) announces the launch, subject to market and other conditions, of an approximately EUR 75M global follow-on...

3M ago

NBTX

Nanobiotix files EUR75M ordinary shares offering

16:23 EDT Nanobiotix (NBTX) files EUR75M ordinary shares offering Published first on TheFly – the ultimate source for...

3M ago

NBTX

Nanobiotix price target raised to EUR 60 from EUR 34 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Nanobiotix (NBTX) to EUR 60 from EUR 34 and keeps...

3M ago

NBTX

Nanobiotix announces FDA acceptance of NANORAY-312 study protocol amendment

Nanobiotix (NBTX) announced FDA acceptance of a protocol amendment to the ongoing pivotal NANORAY-312 study. This protocol amendment,...

4M ago

JNJ

NBTX

Nanobiotix price target raised to $30 from $3.50 at UBS

UBS raised the firm’s price target on Nanobiotix (NBTX) to $30 from $3.50 and keeps a Neutral rating...

4M ago

NBTX

Nanobiotix: Platform Expansion Potential and Risk-Adjusted NBTXR3 Valuation Support Buy Rating

Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Nanobiotix and keeping the price target at...

4M ago

NBTX

Nanobiotix price target raised to EUR 34 from EUR 32 at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Nanobiotix (NBTX) to EUR 34 from EUR...

4M ago

NBTX

Nanobiotix Earnings Call: Deeper J&J Ties, Lower Loss

Nanobiotix SA (($FR:NANO)) has held its Q4 earnings call. Read on for the main highlights of the call....

5M ago

Nanobiotix price target raised to $36 from $26 at Guggenheim

Guggenheim raised the firm’s price target on Nanobiotix (NBTX) to $36 from $26 and keeps a Buy rating...

5M ago

NBTX

Nanobiotix: Late-Stage NBTXR3 Pipeline and Partnerships Underpin Buy-Rated Risk-Reward Profile

TD Cowen analyst Tara Bancroft has maintained their bullish stance on NBTX stock, giving a Buy rating today....

5M ago

NBTX

Nanobiotix price target raised to $37 from $26 at Leerink

Leerink analyst Jonathan Chang raised the firm’s price target on Nanobiotix (NBTX) to $37 from $26 and keeps...

5M ago

NBTX

0QAV FAQ

What was Nanobiotix SA’s price range in the past 12 months?

Nanobiotix SA lowest share price was €7.00 and its highest was €47.60 in the past 12 months.

What is Nanobiotix SA’s market cap?

Nanobiotix SA’s market cap is €1.93B.

When is Nanobiotix SA’s upcoming earnings report date?

Nanobiotix SA’s upcoming earnings report date is Sep 30, 2026 which is in 40 days.

How were Nanobiotix SA’s earnings last quarter?

Currently, no data Available

Is Nanobiotix SA overvalued?

According to Wall Street analysts Nanobiotix SA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nanobiotix SA pay dividends?

Nanobiotix SA pays a Notavailable dividend of €0.285 which represents an annual dividend yield of N/A. See more information on Nanobiotix SA dividends here

What is Nanobiotix SA’s EPS estimate?

Nanobiotix SA’s EPS estimate is -0.25.

How many shares outstanding does Nanobiotix SA have?

Nanobiotix SA has 50,619,583 shares outstanding.

What happened to Nanobiotix SA’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Nanobiotix SA?

Currently, no hedge funds are holding shares in GB:0QAV

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Nanobiotix SA

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

Nanobiotix (0QAV) Earnings & Revenues

Historic Earnings Reports

0QAV Stock 12 Month Forecast

Average Price Target

€55.00

▲(90.84% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"€4","61":"€61","18.25":"€18.25","32.5":"€32.5","46.75":"€46.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€55.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€45.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,18.25,32.5,46.75,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.94,35.94461538461538,37.949230769230766,39.95384615384615,41.958461538461535,43.96307692307692,45.9676923076923,47.972307692307695,49.97692307692307,51.98153846153846,53.98615384615384,55.99076923076923,57.995384615384616,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.94,35.559999999999995,37.18,38.8,40.42,42.04,43.66,45.28,46.9,48.519999999999996,50.14,51.76,53.379999999999995,{"y":55,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.94,34.79076923076923,35.64153846153846,36.49230769230769,37.34307692307692,38.19384615384615,39.04461538461538,39.895384615384614,40.746153846153845,41.596923076923076,42.44769230769231,43.29846153846154,44.14923076923077,{"y":45,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.897,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.65,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.14,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.399,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.36,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.92,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.55,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.203,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.194,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.58,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.736,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.94,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >